← boardnext 2027-08-31
CANF
Can-Fite BioPharmadistress 7/10 · high distress / dilution risk$3.23-2%today-85% from 52w high
Oncology 2Metabolic / Obesity 1
Lead: Plaque Psoriasis · target A3AR · est. market ~$30B (approx, global)
Revenue
pre-revenue
Liquidity
$6M
Runway
0.6 yrs
Shares 1y
0%
Price & events
-22.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
-2.7%
1W
+5.9%
1M
+11.0%
3M
-27.7%
6M
-84.3%
1Y
-95.5%
2Y
-99.2%
5Y
-99.1%
All
Overview
- Market Cap
- $8.46M
- Volume
- 11.07K
- 52 Week Range
- $2.75 – $21.00
- Total Shares
- 2.62M
- Float Shares
- 2.14M
- Short %
- 15.09%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 6.55%
- RVOL
- 0.00x
- Beta
- 0.02
Pipeline stages · 2 programs
piclidenoson
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Namodenoson 25mgA3AR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-08-31 Estimated 50% readout ~2027-10-15 | Phase 2 | Piclidenoson | Lowe Syndrome | — | not yet recruiting |
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | piclidenoson | Plaque Psoriasis | — | not yet recruiting |
| 2026-07-15 Estimated 50% readout ~2026-08-29 | Phase 2 | Namodenoson 25mg | Pancreatic Adenocarcinoma, Pancreatic Cancer | 20 | recruiting |
| 2026-02 | Phase 3 | Namodenoson | Hepatocellular Carcinoma, Cirrhosis | 471 | recruiting |
| 2025-04-15 | Phase 2 | Namodenoson | NASH - Nonalcoholic Steatohepatitis | 114 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+148% upside) · 1 analysts
- 2026-07-02HC Wainwright & Co.Buy
- 2026-05-13D. Boral CapitalHold → Buy
- 2026-05-12HC Wainwright & Co.Buy
- 2025-12-24D. Boral CapitalBuy → Hold
- 2025-12-17D. Boral CapitalBuy
- 2025-11-18D. Boral CapitalBuy
Competitors — A3AR
- none identified
Recent news
- 2026-07-20Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One - Business Wire
- 2026-07-20Can-Fite’s pancreatic cancer study accepted for ESMO presentation By Investing.com - Investing.com Nigeria
- 2026-07-20Can-Fite BioPharma Announces ESMO 2026 Poster Presentation of Positive Phase 2a Namodenoson Data in Advanced Pancreatic Cancer - Quiver Quantitative
- 2026-07-20Can-Fite’s pancreatic cancer study accepted for ESMO presentation - Investing.com
- 2026-07-20Can-Fite BioPharma (NYSE: CANF) to present Phase 2a pancreatic cancer data - Stock Titan
- 2026-07-20Can-Fite Positive Phase 2a Pancreatic Cancer Study Data - GlobeNewswire
- 2026-07-15Glenn Youngkin, 74th Governor of Virginia and former Carlyle Co-CEO, Joins Red Cell Partners as Chairman - Business Wire
- 2026-07-15Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.